Do opioid analgesics cause bronchospasm in patients with asthma or chronic obstructive pulmonary disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Do Opioids Cause Bronchospasm?

Opioids rarely cause clinically significant bronchospasm in patients with asthma or COPD, and when bronchospasm does occur, it is primarily mediated by histamine release from certain opioid drugs rather than a direct pharmacologic effect on bronchial smooth muscle. 1, 2

Mechanism and Clinical Reality

  • Histamine-mediated bronchospasm is uncommon and drug-specific. Certain opioids (particularly morphine, codeine, and meperidine) can trigger mast cell degranulation and histamine release, but this rarely provokes bronchospasm even in susceptible patients 1

  • The British Thoracic Society guidelines acknowledge a theoretical risk of bronchospasm with nebulized opioids and recommend pretreatment with β-agonists before administering nebulized morphine, diamorphine, or fentanyl for palliation of breathlessness 3

  • Histamine released by opioids in normal therapeutic doses does not lead to anaphylactoid reactions or clinically significant bronchospasm in normal patients 1

Primary Respiratory Concern: Depression, Not Bronchospasm

  • The dominant respiratory risk from opioids is ventilatory impairment (respiratory depression), not bronchospasm 4, 5, 1

  • Opioid-induced ventilatory impairment occurs through three mechanisms: depression of the brainstem respiratory center, reduced upper airway muscle tone causing obstruction, and increased sedation with reduced arousal 5

  • Respiratory depression is the mechanism that causes morbidity and mortality in COPD patients receiving opioids, not bronchospasm 6, 7, 8

Evidence from COPD and Asthma Populations

  • Among 169,517 older adults with COPD receiving new opioid prescriptions, 2.9% experienced adverse pulmonary events within 30 days, but these events were respiratory depression-related (COPD exacerbations, pneumonia, respiratory failure), not bronchospasm 7

  • Concurrent use of opioids with benzodiazepines in COPD patients increases the risk of respiratory hospitalization (adjusted OR 2.32), again through ventilatory impairment rather than bronchospasm 6

  • The British Thoracic Society notes that bronchodilators are not contraindicated in any patient group with cystic fibrosis, implying that opioid-induced bronchospasm is not a recognized clinical barrier 3

Practical Clinical Approach

When prescribing opioids to patients with reactive airway disease:

  • Do not routinely withhold opioids due to bronchospasm concerns in patients with asthma or COPD—the risk is negligible compared to the risk of respiratory depression 1, 2

  • If using nebulized opioids for palliative breathlessness, pretreat with β-agonist bronchodilators as a precautionary measure 3

  • Avoid morphine and codeine in patients with severe respiratory compromise not because of bronchospasm risk, but because their active metabolites accumulate and worsen respiratory depression 9

  • Consider buprenorphine as the safest opioid option in patients with COPD or respiratory compromise due to its ceiling effect on respiratory depression 9

  • Monitor for respiratory depression (reduced respiratory rate, oxygen desaturation, hypercapnia), not bronchospasm, as the primary safety concern 10, 5

Common Pitfall to Avoid

  • Do not confuse opioid-induced respiratory depression with bronchospasm. Patients experiencing opioid toxicity present with reduced respiratory rate, sedation, and hypercapnia—not wheezing, chest tightness, or prolonged expiration typical of bronchospasm 10, 5, 1

  • The theoretical concern about histamine-mediated bronchospasm has never been demonstrated to cause clinically significant harm in appropriately monitored patients 9, 1

References

Research

Opioid effect on lungs.

Respirology (Carlton, Vic.), 2013

Guideline

adult cancer pain, version 3.2019, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2019

Guideline

Buprenorphine’s Ceiling Effect on Respiratory Depression and Evidence‑Based Clinical Guidance

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.